ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $3.37B

      Shares

      41.2M

      % of Portfolio

      2.45%

      Average Buy Price

      $32.3

      Avg closing price
      Price range

      40 PRIMECAP Management Astrazeneca plc Trades

      PRIMECAP Management's position in Astrazeneca plc is currently worth $3.37B. That's 2.45% of their equity portfolio (9th largest holding). The investor owns 1.35% of the outstanding Astrazeneca plc stock. The first Astrazeneca plc trade was made in Q3 2015. Since then PRIMECAP Management bought shares eighteen more times and sold shares on 21 occasions. The stake costed the investor $1.33B, netting the investor a gain of 153% so far.

      Avg closing price
      Price range
      Increased shares by 1.3% (+539k shares) Q2 2025
      Avg closing price $70.05
      Price range $64.87 - $75.00
      Sold 0.9% shares (-358k shares) Q1 2025
      Avg closing price $72.18
      Price range $65.37 - $77.96
      Sold 2.3% shares (-961k shares) Q4 2024
      Avg closing price $69.86
      Price range $63.20 - $79.58
      Sold 1.4% shares (-617k shares) Q3 2024
      Avg closing price $80.76
      Price range $76.67 - $87.62
      Sold 0.8% shares (-348k shares) Q2 2024
      Avg closing price $75.24
      Price range $66.81 - $80.83
      Sold 0.1% shares (-41.9k shares) Q1 2024
      Avg closing price $66.21
      Price range $61.03 - $69.57
      Sold 2.1% shares (-902k shares) Q4 2023
      Avg closing price $65.00
      Price range $61.89 - $69.28
      Sold 0.4% shares (-188k shares) Q3 2023
      Avg closing price $68.29
      Price range $64.85 - $71.70
      Sold 2.9% shares (-1.31M shares) Q2 2023
      Avg closing price $73.57
      Price range $69.91 - $75.81
      Increased shares by 0.9% (+403k shares) Q1 2023
      Avg closing price $67.27
      Price range $63.15 - $71.60
      Sold 1.4% shares (-627k shares) Q4 2022
      Avg closing price $62.70
      Price range $54.21 - $70.44
      Sold 0.4% shares (-200k shares) Q3 2022
      Avg closing price $63.43
      Price range $53.02 - $68.26
      Sold 1.1% shares (-504k shares) Q2 2022
      Avg closing price $65.61
      Price range $59.26 - $71.14
      Sold 0.8% shares (-373k shares) Q1 2022
      Avg closing price $59.96
      Price range $55.72 - $67.12
      Sold 3.3% shares (-1.58M shares) Q4 2021
      Avg closing price $58.83
      Price range $54.02 - $63.83
      Sold 0.9% shares (-438k shares) Q3 2021
      Avg closing price $58.20
      Price range $55.56 - $60.79
      Sold 2.4% shares (-1.21M shares) Q2 2021
      Avg closing price $54.86
      Price range $48.42 - $60.18
      Sold 0.4% shares (-196k shares) Q1 2021
      Avg closing price $50.26
      Price range $47.16 - $54.44
      Sold 2.7% shares (-1.39M shares) Q4 2020
      Avg closing price $52.96
      Price range $48.52 - $58.02
      Sold 4.0% shares (-2.16M shares) Q3 2020
      Avg closing price $55.61
      Price range $53.07 - $61.10

      News about Astrazeneca plc - ADR and PRIMECAP Management

      Princeton Global Asset Management LLC Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

      Princeton Global Asset Management LLC Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

      Princeton Global Asset Management LLC grew its position in shares of AstraZeneca PLC (NASDAQ:AZN ¨C Free Report) by 77.5% during the third quarter, according ...

      The AM Reporter The AM Reporter, over 1 year ago
      AIM ImmunoTech Inc.: AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen? (rintatolimod) in Combination with AstraZeneca''s Imfinzi? (durvalumab) for the Treatment of Pancreatic Cancer

      AIM ImmunoTech Inc.: AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen? (rintatolimod) in Combination with AstraZeneca''s Imfinzi? (durvalumab) for the Treatment of Pancreatic Cancer

      First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what th...

      Finanz Nachrichten Finanz Nachrichten, over 1 year ago
      Moran Wealth Management LLC Sells 453 Shares of AstraZeneca PLC (NASDAQ:AZN)

      Moran Wealth Management LLC Sells 453 Shares of AstraZeneca PLC (NASDAQ:AZN)

      Moran Wealth Management LLC decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN ¨C Free Report) by 1.4% in the 2nd quarter, Holdings Channel repor...

      The AM Reporter The AM Reporter, almost 2 years ago
      Why Legend Mining, Medibank, Starpharma, and Weebit Nano shares are sinking

      Why Legend Mining, Medibank, Starpharma, and Weebit Nano shares are sinking

      In afternoon trade, the? S&P/ASX 200 Index (ASX: XJO) looks set to end its losing streak. At the time of writing, the benchmark index is up 0.5% to 7,116 poi...

      Newswires Newswires, about 2 years ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×